ADAG
ADAG clinical trials: Adagene Inc.
Every trial on ClinicalTrials.gov where Adagene Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 7
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ADAG on the catalyst calendar · ADAG registry changes
- Primary completion Jun 30, 2027Sponsor estimatePhase 1/Phase 2NCT05405595ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsAdagene Inc · Advanced/Metastatic Solid TumorsRecruitingADAGLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2025ActualPhase 1NCT05614258Study of ADG206 in Subjects With Advanced/Metastatic Solid TumorsAdagene Inc · Advanced/Metastatic Solid TumorsActive, not recruitingADAGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2024ActualPhase 1NCT04501276A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsAdagene Inc · Advanced/Metastatic Solid TumorsCompletedADAGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2024ActualPhase 1/Phase 2NCT04645069ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid TumorsAdagene Inc · Advanced/Metastatic Solid TumorsCompletedADAGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2022ActualPhase 1NCT05277402ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsAdagene Inc · Advanced/Metastatic Solid TumorsCompletedADAGLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2022ActualPhase 1NCT03707093Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaAdagene Inc · Solid Tumors, Non-Hodgkin LymphomaCompletedADAGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2021ActualPhase 1NCT04111445Study of ADG116 in Patients With Advanced/Metastatic Solid TumorsAdagene Inc · Solid TumorTerminatedADAGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 1/Phase 2NCT04524871A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver...Hoffmann-La Roche · Advanced Liver CancersActive, not recruitingTPSTCollaboratorADAGCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT06846268Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal CancerNational University Hospital, Singapore · Locally Advanced Colorectal CancerRecruitingADAGCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1/Phase 2NCT05491083Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast CancerNational University Hospital, Singapore · Advanced Solid TumorRecruitingADAGCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT05275777A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast CancerNational University Hospital, Singapore · HER2-negative Breast CancerActive, not recruitingADAGCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2024Sponsor estimatePhase 1/Phase 2NCT05236608A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLCNational University Hospital, Singapore · Metastatic Non Small Cell Lung CancerUnknown statusADAGCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner